MK2206, a selective AKT inhibitor, modulates ovarian cancer cell line sensitivity to carboplatin plus paclitaxel

被引：0
|
作者：
Zgheib, N. Bou [1 ]
Marchion, D. [1 ]
Xiong, Y. [1 ]
Stickles, X. [1 ]
Judson, P. [1 ]
Hakam, A. [1 ]
Bosquet, J. Gonzalez [1 ]
Wenham, R. [1 ]
Apte, S. [1 ]
Lancaster, J. [1 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
342
引用
收藏
页码：S140 / S140
页数：1
相关论文
共 50 条
  • [41] Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer
    Meteran, Hanieh
    Knudsen, Anja Or
    Jorgensen, Trine Lembrecht
    Nielsen, Dorte
    Herrstedt, Jorn
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [42] Hemiasterlin derivative (R)(S)(S)-BF65 and Akt inhibitor MK-2206 synergistically inhibit SKOV3 ovarian cancer cell growth
    Lai, Wei-Ting
    Cheng, Kai-Lin
    Baruchello, Riccardo
    Rondanin, Riccardo
    Marchetti, Paolo
    Simoni, Daniele
    Lee, Ray M.
    Guh, Jih-Hwa
    Hsu, Lih-Ching
    BIOCHEMICAL PHARMACOLOGY, 2016, 113 : 12 - 23
  • [43] Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib
    Lara, Primo N., Jr.
    Longmate, Jeff
    Mack, Philip C.
    Kelly, Karen
    Socinski, Mark A.
    Salgia, Ravi
    Gitlitz, Barbara
    Li, Tianhong
    Koczywas, Mariana
    Reckamp, Karen L.
    Gandara, David R.
    CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4321 - 4326
  • [44] Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
    Agarwal, Ekta
    Chaudhuri, Anathbandhu
    Leiphrakpam, Premila D.
    Haferbier, Katie L.
    Brattain, Michael G.
    Chowdhury, Sanjib
    BMC CANCER, 2014, 14
  • [45] Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
    Ekta Agarwal
    Anathbandhu Chaudhuri
    Premila D Leiphrakpam
    Katie L Haferbier
    Michael G Brattain
    Sanjib Chowdhury
    BMC Cancer, 14
  • [46] Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer
    du Bois, Andreas
    Herrstedt, Jorn
    Hardy-Bessard, Anne-Claire
    Mueller, Hans-Helge
    Harter, Philipp
    Kristensen, Gunnar
    Joly, Florence
    Huober, Jens
    Avall-Lundqvist, Elisabeth
    Weber, Beatrice
    Kurzeder, Christian
    Jelic, Svetislav
    Pujade-Lauraine, Eric
    Burges, Alexander
    Pfisterer, Jacobus
    Gropp, Martina
    Staehle, Anne
    Wimberger, Pauline
    Jackisch, Christian
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4162 - 4169
  • [47] Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: Preliminary results of a phase I study
    Lhomme, C
    Kerbrat, P
    Lejeune, C
    Guastalla, JP
    Fumoleau, P
    Goupil, A
    Heron, JF
    Cassin, MA
    Pruvot, I
    Soares, JA
    Chazard, M
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 48 - 54
  • [48] A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER plus ) metastatic breast cancer (MBC)
    Ma, Cynthia X.
    Gao, Feng
    Naughton, Michael
    Pluard, Timothy J.
    Sorscher, Steven
    Creekmore, Allison N.
    Guo, Zhanfang
    Dehdashti, Farrokh
    Park, Ben Ho
    Lockhart, Albert C.
    Doyle, L. Austin
    Ellis, Matthew J.
    Erlanger, Bracha
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
    Blagden, Sarah P.
    Hamilton, Anne L.
    Mileshkin, Linda
    Wong, Shirley
    Michael, Agnieszka
    Hall, Marcia
    Goh, Jeffrey C.
    Lisyanskaya, Alla S.
    DeSilvio, Michelle
    Frangou, Eleni
    Stronach, Euan A.
    Gopalakrishna, Prashanth
    Meniawy, Tarek M.
    Gabra, Hani
    CLINICAL CANCER RESEARCH, 2019, 25 (05) : 1472 - 1478
  • [50] Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study
    Delanoy, N.
    Ashton, E.
    Mebarki, S.
    Gisselbrecht, M.
    Nicaise, B.
    Azais, H.
    Koual, M.
    Mongardon, A-S. Bats
    Fournier, L.
    Le Frere-Belda, M-A.
    Medioni, J.
    Paillaud, E.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S796 - S796
12345